Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD
Clinical Journal of the American Society of Nephrology · 2026-03 · 21 (3) · 401-413
DOI: 10.2215/cjn.0000000928 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 12.01.2026. Verfasst von Yunqi Shi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Endothelin Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Beijing Anzhen Hospital High Level Research Funding, Beijing Municipal Hospital Scientific Research Cultivation Plan, Beijing Hospital Management Center's Youth Talent Training "Young Seedlings" Program.
Abstract (Originalsprache)
Key Points Endothelin receptor antagonists should be applied for patients with CKD whose proteinuria and high risk of kidney function decline remains insufficiently controlled. We recommend that endothelin A receptor-selective endothelin receptor antagonists should be preferable for patients with CKD with consideration for combination therapy with sodium-glucose cotransporter-2 inhibitors.
Background
Endothelin receptor antagonists (ERAs) are considered a potential effective treatment to reduce proteinuria and protect kidney function for patients with CKD; however, they may cause fluid retention. We conducted this meta-analysis to quantify the efficacy and safety of ERAs in CKD.
Methods
We searched Cochrane Library, Ovid Medline, and Ovid Embase for randomized controlled trials up to January 2025. Continuous and dichotomous data were reported as standardized mean differences (SMDs) with 95% confidence intervals (CIs) and risk ratios (RRs) with 95% CIs, respectively.
Results
Fourteen trials enrolling 6412 patients were included. Compared with the control group, ERAs decreased the risk of ESKD (RR=0.76, 95% CI [0.61 to 0.96]), reduced the urine protein-to-creatinine ratio (SMD=−0.56, 95% CI [−0.78 to −0.35]) and urine albumin-to-creatinine ratio (SMD=−0.64, 95% CI [−0.75 to −0.53]), achieved more frequent complete proteinuria remission (RR=2.61, 95% CI [1.84 to 3.71]) and partial proteinuria remission (RR=1.51, 95% CI [1.32 to 1.73]), slowed the decline of eGFR in the subgroup with a follow-up duration of at least 1 year (SMD=0.18, 95% CI [0.04 to 0.32]), improved the chronic eGFR slope (SMD=0.15, 95% CI [0.01 to 0.30]), and decreased systolic BP (SMD=−0.53, 95% CI [−0.76 to −0.30]) and diastolic BP (SMD=−0.78, 95% CI [−1.18 to −0.38]). Although the risk was increased in B-type natriuretic peptide (SMD=0.08, 95% CI [0.01 to 0.16]) and body weight (SMD=0.15, 95% CI [0.01 to 0.29]), ERAs did not increase the incidence of edema, fluid retention, or heart failure. The risk of hypotension was higher with ERAs compared with the control group (RR=1.92, 95% CI [1.36 to 2.70]).
Conclusion
These findings suggest that ERAs may reduce proteinuria, prevent kidney disease progression, and lower BP in individuals with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Yunqi Shi, Nan Ye, Guoqin Wang, Hong Cheng
Förderung
- Beijing Anzhen Hospital High Level Research Funding
- Beijing Municipal Hospital Scientific Research Cultivation Plan
- Beijing Hospital Management Center's Youth Talent Training "Young Seedlings" Program
- Beijing Hospital Management Center's Youth Talent Training “Young Seedlings” Program
Zitieren
APA
Shi, Y., Ye, N., Wang, G., & Cheng, H. (2026). Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD. Clinical Journal of the American Society of Nephrology, 21(3), 401-413. https://doi.org/10.2215/cjn.0000000928
Vancouver
Shi Y, Ye N, Wang G, Cheng H. Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD. Clinical Journal of the American Society of Nephrology. 2026;21(3):401-413. doi:10.2215/cjn.0000000928
BibTeX
@article{Shi2026,
author = {Shi, Yunqi and Ye, Nan and Wang, Guoqin and Cheng, Hong},
title = {Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
volume = {21},
number = {3},
pages = {401--413},
doi = {10.2215/cjn.0000000928}
}
EUVIMED